Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness

Via, Michael A.; Potenza, Matthew; Hollander, Jason M.; Li, Xuan; Peng, Yangyang; Li, Jianhua; Sun, Li; Zaidi, Mone; Mechanick, Jeffrey I.

doi:10.1177/0885066611402156

Cited by 24 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is limited evidence examining the efficacy of bisphosphonates in this setting. A randomised controlled trial identified in the search strategy and excluded from this analysis, reported a transient decrease in serum B-CTX in chronic critically ill patients receiving a single intravenous dose of ibandronate compared to placebo [43]. In addition the decrease in in the bone turnover marker (serum OC) observed in postmenopausal women receiving ibandronate [44] was not observed in this study, supporting the theory that bone formation and resorption is uncoupled in critical illness.…”

Section: Discussionsupporting

confidence: 55%

The association between critical illness and changes in bone turnover in adults: a systematic review

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

The association between critical illness and changes in bone turnover in adults: a systematic review

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Protocol‐based enteral feeding and glycemic control are primary recommendations, with emerging investigations for mobility protocols and endocrine therapy (eg, treatment for bone resorption and vitamin D deficiency) 446 . ‐ 448 …”

Section: P Chronically Critically Illmentioning

confidence: 99%

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

McClave

Taylor

Martindale

et al. 2016

J Parenter Enteral Nutr

2,643

1,248

View full text Add to dashboard Cite

“…A small study reported a transient decrease in bone resorption markers after administration of intravenous ibandronate [36], and a retrospective propensity-matched cohort study described an association between pre-ICU bisphosphonate use and reduced mortality [37]. In addition, serial computed tomography (CT) assessment of vertebral BMD revealed bisphosphonate users had lower baseline bone density and an attenuated decrease in BMD during critical illness.…”

Section: Discussionmentioning

confidence: 99%

The association of time and medications with changes in bone mineral density in the 2 years after critical illness

et al. 2017

View full text Add to dashboard Cite

BackgroundCritical illness is associated with increased risk of fragility fracture and loss of bone mineral density (BMD), although the impact of medication exposures (bone anti-fracture therapy or glucocorticoids) and time remain unexplored. The objective of this study was to describe the association of time after ICU admission, and post-ICU administration of bone anti-fracture therapy or glucocorticoids after critical illness, with change in BMD.MethodsIn this prospective observational study, conducted in a tertiary hospital ICU, we studied adult patients requiring mechanical ventilation for at least 24 hours and measured BMD annually for 2 years after ICU discharge. We performed mixed linear modelling to describe the association of time, and post-ICU administration of anti-fracture therapy or glucocorticoids, with annualised change in BMD.ResultsNinety-two participants with a mean age of 63 (±15) years had at least one BMD assessment after ICU discharge. In women, a greater loss of spine BMD occurred in the first year after critical illness (year 1: -1.1 ± 2.0% vs year 2: 3.0 ± 1.7%, p = 0.02), and anti-fracture therapy use was associated with reduced loss of BMD (femur 3.1 ± 2.4% vs -2.8 ± 1.7%, p = 0.04, spine 5.1 ± 2.5% vs -3.2 ± 1.8%, p = 0.01). In men anti-fracture and glucocorticoid use were not associated with change in BMD, and a greater decrease in BMD occurred in the second year after critical illness (year 1: -0.9 ± 2.1% vs year 2: -2.5 ± 2.1%, p = 0.03).ConclusionsIn women a greater loss of spine BMD was observed in the first year after critical illness, and anti-fracture therapy use was associated with an increase in BMD. In men BMD loss increased in the second year after critical illness. Anti-fracture therapy may be an effective intervention to prevent bone loss in women after critical illness.Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-017-1657-6) contains supplementary material, which is available to authorized users.

show abstract

Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness

Abstract: A single dose of intravenous ibandronate causes a significant but transient reduction in osteoclast activity in patients with CCI, which persists over a 6-day period.

Cited by 24 publications

References 30 publications

The association between critical illness and changes in bone turnover in adults: a systematic review

The association between critical illness and changes in bone turnover in adults: a systematic review

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

The association of time and medications with changes in bone mineral density in the 2 years after critical illness

Contact Info

Product

Resources

About